<DOC>
	<DOCNO>NCT01482962</DOCNO>
	<brief_summary>This phase 3 , randomize , 2-arm , open-label , international trial evaluate alisertib compare single-agent treatment , select investigator offer option pralatrexate gemcitabine romidepsin , patient relapse refractory peripheral T-cell lymphoma ( PTCL ) . Note : romidepsin use single-agent comparator country permit use time .</brief_summary>
	<brief_title>Alisertib ( MLN8237 ) Investigator 's Choice Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Aminopterin</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<criteria>Male female patient age 18 old Patients PTCL accord World Health Organization ( WHO ) criterion relapse refractory least 1 prior systemic , cytoxic therapy PTCL . Patients must receive conventional therapy prior therapy . Cutaneousonly disease permit . Patients must document evidence progressive disease . Tumor biopsy available central hematopathologic review Measurable disease accord IWG criterion Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Female patient post menopausal least 1 year , surgically sterile , agree practice 2 effective method contraception 30 day last dose study drug agree abstain heterosexual intercourse . Male patient agree practice effective barrier contraception 6 month last dose alisertib agree abstain heterosexual intercourse Suitable venous access Voluntary write consent Exclusion Criteria Known central nervous system lymphoma Systemic antineoplastic therapy , immunotherapy , investigational agent radiation therapy within 4 week first dose study treatment concomitant use study Prior administration Aurora A kinasetargeted agent , include alisertib ; 3 comparator drug ( pralatrexate , romidepsin gemcitabine ; know hypersensitivity ) History uncontrolled sleep apnea syndrome condition could result excessive daytime sleepiness Cardiac condition specify study protocol , include leave ventricular ejection fraction ( LVEF ) &lt; 40 % Concomitant use medicine specify study protocol Patients abnormal gastric bowel function require continuous treatment H2receptor antagonists proton pump inhibitor Known active infection human immunodeficiency virus ( HIV ) , hepatitis B virus , hepatitis C Autologous stem cell transplant le 3 month prior enrollment Patients undergone allogeneic stem cell organ transplantation time Inadequate blood level , bone marrow organ function specify study protocol The patient must recover National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) Grade â‰¤ 1 toxicity , patient 's baseline status ( except alopecia ) , deem irreversible effect prior cancer therapy Major surgery , serious infection , infection require systemic antibiotic therapy within 14 day prior first dose study treatment Female patient breastfeed pregnant Coexistent second malignancy history prior solid organ malignancy within previous 3 year Serious medical psychiatric illness laboratory abnormality could , investigator 's opinion , potentially interfere completion treatment accord protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>